Anlon Healthcare Ltd (AHCL) is currently trading at 16.23 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Anlon Healthcare manufactures pharmaceutical APIs and high‑purity intermediates from its Rajkot facility, provides custom manufacturing (CDMO) services, and has expanded via an IPO in August 2025; the company reports regulatory filings including 21 DMFs and commercial presence across 15 countries, positioning Anlon Healthcare as a research-driven API/intermediate manufacturer focused on regulated market customers. The company reported a sharp year‑on‑year operational improvement: Q3 total income rose to INR 35.78 crore from INR 9.38 crore a year earlier, EBITDA of INR 12.54 crore at 35.1% margin and a return to PAT of INR 5.15 crore, reflecting stronger product mix, operating leverage and an expanding CDMO pipeline for Anlon Healthcare. Anlon Healthcare is pursuing a sizeable inorganic and organic expansion plan: management completed the Apiqo Organics deal, is proposing Bizotic Life Science acquisition, and announced greenfield/organic expansions with planned capital expenditure of about INR 100–120 crore to materially increase installed capacity and support projected revenue growth for Anlon Healthcare. The company emphasises regulatory and product pipeline progress: management has 21 DMFs filed, expects commercialisation of several DMF products next year, is developing three CDMO molecules for global innovators with validations underway, and targets broader regulated‑market penetration and new API launches to diversify Anlon Healthcare's therapeutic exposure and margin profile.

Over the past 52 weeks, Anlon Healthcare Ltd has traded between a low of ₹10.15 and a high of ₹17.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Anlon Healthcare Ltd has a market capitalization of approximately 826.51. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Anlon Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.47 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 826.51 Cr, Anlon Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Anlon Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Anlon Healthcare Ltd is 29.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

They approved audited FY26 financial statements, director appointments, an increase in authorised share capital to ₹130 crore, and a preferential issue of up to 8,58,83,617 shares linked to acquisitions.

The 13th AGM is scheduled for September 5, 2026 at 11:00 am (IST) and will be held via video conference.

The AGM is scheduled for September 5, 2026 at 11:00 am and will be conducted via video conference.

It published extracts in the Financial Express (English and Gujarati editions) on August 1, 2026, for the quarter ended June 30, 2026.